Has change come to biology?
By John Timmer,
arts technica
| 02. 02. 2009
Stem cell research under Obama
President Obama's promise to restore science to its rightful place has raised the hopes of biologists that there will be swift action on what many view as a serious hindrance to biology: restrictions on the use of human embryonic stem cells (hESCs). Federal funding of hESC research has been limited to lines created before August 9th, 2001—nearly nine years ago—and most of the acceptable lines have since been found to be inappropriate for clinical research; ethical issues involving informed consent affect the remaining handful. On Tuesday, the New York Stem Cell foundation hosted a panel that discussed how a lifting of the Bush-era restrictions on hESC research is likely to change hESC research.
The panel included two members that had been part of the Obama transition team: Alta Charo, who focuses on bioethics at the University of Wisconsin Law School, and Nobel Laureate Harold Varmus of Sloan-Kettering, who is now serving on Obama's Science and Technology advisory panel. Lawrence Tabak of the NIH provided some perspective on what his agency would need to do, and Harvard's Kevin Eggan spoke as...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...